吸入特雷普罗斯尼尔治疗异常性肺纤维化
Steven D Nathan1, Peter Smith2, Chunqin Deng2
1Inova Fairfax Hospital, Falls Church, VA.
The New England journal of medicine
|March 11, 2026
概括
与安慰剂相比,在52周内,吸入的特雷普罗斯提尼尔在异常性肺纤维化 (IPF) 患者的强迫生命能力 (FVC) 的下降较小,并且减少了临床恶化事件.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 临床前数据表明,吸入的特雷普罗斯尼尔具有抗纤维素特性,对异常性肺纤维化 (IPF) 有益.
- 临床观察证据支持吸入式特雷普罗斯尼在治疗IPF的潜在疗效.
研究的目的:
- 在IPF患者中,评估吸入式特雷普罗斯尼尔与安慰剂的疗效和安全性.
- 评估吸入特雷普罗斯丁尼尔对52周肺功能和临床结果的影响.
主要方法:
- 第三阶段,双盲,随机试验,涉及593名IPF患者,分别接受吸入式特雷沙或安慰剂.
- 主要终点:52周绝对强迫生命能力 (FVC) 的变化.
- 二级终点包括临床恶化,IPF恶化,死亡率和FVC百分比,生活质量和扩散能力的变化.
主要成果:
- 吸入式特雷普罗斯尼尔显示FVC中位数变化为-49.9毫升,与安慰剂相比为-136.4毫升 (差异:95.6毫升;P<0.001).
- 临床恶化发生在27.2%的treprostinil组与39%的安慰剂组 (HR,0.71;P=0.02) 的27.2%.
- 咳是最常见的不良事件;由于不良事件而导致的中止率较高,与treprostinil.
结论:
- 吸入的特雷普罗斯尼尔与IPF患者在52周内FVC下降的速度较慢有关.
- 与安慰剂相比,吸入特雷普罗斯尼尔显著降低了临床恶化事件的发生率.
- 该研究满足了其主要终点,表明吸入特雷普罗斯丁尼在IPF管理中的潜在治疗益处.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
578
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
578
01:25Pulmonary Function Tests
962
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
962
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
529
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
529
01:23Inhaled Medications
947
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
947
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
710
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
710
01:17Other Pulmonary Disorders
1.8K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.8K